Pfizer CEO Slams HHS Over 'Inaccurate' mRNA Vaccine Safety Allegations
Industry Conflict Over mRNA Vaccine Development
Pharmaceutical companies rarely support each other publicly, but a recent clash has emerged between Pfizer and Moderna. The US Department of Health and Human Services (HHS) canceled a $590 million contract with Moderna to develop an mRNA bird flu vaccine. HHS cited concerns that mRNA technology is still under-tested. In response, Pfizer's CEO, Dr. Albert Bourla, stepped forward to defend the technology.
Pfizer’s Stand on mRNA Technology
Dr. Albert Bourla, CEO of Pfizer, countered HHS's claims by highlighting the extensive use of mRNA vaccines. He pointed out that around 1.5 billion mRNA vaccine doses against Covid-19 have been administered globally by Pfizer alone, not including Moderna's contributions. Bourla emphasized that mRNA technology is well-tested and has been a significant tool in fighting the pandemic.
HHS's Decision to Cancel Moderna's Contract
HHS announced the termination of Moderna's contract to develop a pandemic influenza vaccine, specifically targeting the H5N1 avian flu strain. The agency stated that continued investment in Moderna’s mRNA vaccine was not scientifically or ethically justifiable. They criticized the previous administration for funding what they see as an under-tested technology and expressed concerns over safety.
Pfizer’s Advances in Cancer Treatment
While addressing vaccine controversies, Pfizer is making significant strides in cancer research. At the American Society of Clinical Oncology conference, Pfizer presented data on Braftovi, a colorectal cancer drug that has doubled patient survival rates in clinical trials. Dr. Bourla highlighted the urgent need for effective cancer treatments, especially as colorectal cancer rates rise among younger populations.
Vaccine Policy Changes and Public Health
Pfizer expressed concerns over recent policy changes regarding Covid-19 vaccines. The FDA is set to alter approval processes for updated vaccines, and the CDC may no longer recommend vaccines for healthy children and pregnant women. Bourla warned that reducing vaccination rates could lead to the resurgence of diseases like measles and whooping cough, stressing the importance of maintaining high vaccination coverage to prevent outbreaks.
Looking Ahead: Collaboration and Future Challenges
Despite disagreements with HHS on vaccine policies, Pfizer remains committed to working with the government on other health issues, such as cancer research. Dr. Bourla emphasized the importance of the National Institutes of Health and expressed concerns over proposed budget cuts. He highlighted the need for a strong scientific ecosystem to support medical advancements. Looking forward, Pfizer aims to continue its collaboration with federal agencies to address public health challenges effectively.
Conclusion
The ongoing debate between Pfizer and HHS highlights the complexities of vaccine development and public health policy. While Pfizer defends the safety and effectiveness of mRNA technology, HHS remains cautious about its application for new vaccines. As both parties navigate these challenges, the focus remains on ensuring public health through continued research, collaboration, and informed decision-making.
Read the full article here:
cnn.com